- Home
- EOD vs ACRS Comparison
EOD vs ACRS Comparison
Compare EOD & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- ACRS
- Stock Information
- Founded
- EOD 2007
- ACRS 2012
- Country
- EOD United States
- ACRS United States
- Employees
- EOD N/A
- ACRS N/A
- Industry
- EOD Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- EOD Finance
- ACRS Health Care
- Exchange
- EOD Nasdaq
- ACRS Nasdaq
- Market Cap
- EOD 245.9M
- ACRS 230.8M
- IPO Year
- EOD N/A
- ACRS 2015
- Fundamental
- Price
- EOD $5.63
- ACRS $2.50
- Analyst Decision
- EOD
- ACRS Strong Buy
- Analyst Count
- EOD 0
- ACRS 9
- Target Price
- EOD N/A
- ACRS $9.25
- AVG Volume (30 Days)
- EOD 118.1K
- ACRS 1.5M
- Earning Date
- EOD 01-01-0001
- ACRS 11-06-2025
- Dividend Yield
- EOD 9.28%
- ACRS N/A
- EPS Growth
- EOD N/A
- ACRS N/A
- EPS
- EOD N/A
- ACRS N/A
- Revenue
- EOD N/A
- ACRS $15,742,000.00
- Revenue This Year
- EOD N/A
- ACRS N/A
- Revenue Next Year
- EOD N/A
- ACRS N/A
- P/E Ratio
- EOD N/A
- ACRS N/A
- Revenue Growth
- EOD N/A
- ACRS N/A
- 52 Week Low
- EOD $3.73
- ACRS $1.05
- 52 Week High
- EOD $4.71
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- EOD 39.53
- ACRS 58.16
- Support Level
- EOD $5.63
- ACRS $2.25
- Resistance Level
- EOD $5.72
- ACRS $2.61
- Average True Range (ATR)
- EOD 0.07
- ACRS 0.25
- MACD
- EOD -0.02
- ACRS -0.00
- Stochastic Oscillator
- EOD 17.97
- ACRS 63.33
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.